Nexera X2 — X-ceptional insights - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nexera X2 — X-ceptional insights


Nexera X2 – X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.

System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.

Stability
Stability in gradient use has been improved by pump side modifications. Furthermore, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific appli-cations, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method transfer.

Sensitivity
The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applica-tions using a capillary cell with low dispersion. Total reflection and a high energy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.

For more information please visit www.shimadzu.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced

Click here